FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2787869143> ?p ?o ?g. }

• W2787869143 endingPage "725" @default.
• W2787869143 startingPage "714" @default.
• W2787869143 abstract "The cost-effectiveness of population-based panel testing for high- and moderate-penetrance ovarian cancer (OC)/breast cancer (BC) gene mutations is unknown. We evaluate the cost-effectiveness of population-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutation testing compared with clinical criteria/family history (FH) testing in unselected general population women.A decision-analytic model comparing lifetime costs and effects of criteria/FH-based BRCA1/BRCA2 testing is compared with BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing in those fulfilling clinical criteria/strong FH of cancer (≥10% BRCA1/BRCA2 probability) and all women age 30 years or older. Analyses are presented for UK and US populations. Identified carriers undergo risk-reducing salpingo-oophorectomy. BRCA1/BRCA2/PALB2 carriers can opt for magnetic resonance imaging/mammography, chemoprevention, or risk-reducing mastectomy. One-way and probabilistic sensitivity analysis (PSA) enabled model uncertainty evaluation. Outcomes include OC, BC, and additional heart disease deaths. Quality-adjusted life-years (QALYs), OC incidence, BC incidence, and incremental cost-effectiveness ratio (ICER) were calculated. The time horizon is lifetime and perspective is payer.Compared with clinical criteria/FH-based BRCA1/BRCA2 testing, clinical criteria/FH-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing is cost-effective (ICER = £7629.65/QALY or $49 282.19/QALY; 0.04 days' life-expectancy gained). Population-based testing for BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 mutations is the most cost-effective strategy compared with current policy: ICER = £21 599.96/QALY or $54 769.78/QALY (9.34 or 7.57 days' life-expectancy gained). At £30 000/QALY and $100 000/QALY willingness-to-pay thresholds, population-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 panel testing is the preferred strategy in 83.7% and 92.7% of PSA simulations; criteria/FH-based panel testing is preferred in 16.2% and 5.8% of simulations, respectively. Population-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing can prevent 1.86%/1.91% of BC and 3.2%/4.88% of OC in UK/US women: 657/655 OC cases and 2420/2386 BC cases prevented per million.Population-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing is more cost-effective than any clinical criteria/FH-based strategy. Clinical criteria/FH-based BRCA1/BRCA2/RAD51C/RAD51D/BRIP1/PALB2 testing is more cost-effective than BRCA1/BRCA2 testing alone." @default.
• W2787869143 created "2018-02-23" @default.
• W2787869143 creator A5007042275 @default.
• W2787869143 creator A5023433214 @default.
• W2787869143 creator A5023667273 @default.
• W2787869143 creator A5027945638 @default.
• W2787869143 creator A5038773254 @default.
• W2787869143 creator A5040745482 @default.
• W2787869143 creator A5047173565 @default.
• W2787869143 creator A5050870337 @default.
• W2787869143 creator A5054081132 @default.
• W2787869143 creator A5060675696 @default.
• W2787869143 creator A5061826468 @default.
• W2787869143 creator A5067052917 @default.
• W2787869143 creator A5081082018 @default.
• W2787869143 creator A5081607480 @default.
• W2787869143 creator A5082989514 @default.
• W2787869143 date "2018-01-18" @default.
• W2787869143 modified "2023-09-30" @default.
• W2787869143 title "Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women" @default.
• W2787869143 cites W1540615297 @default.
• W2787869143 cites W1563439685 @default.
• W2787869143 cites W1577886831 @default.
• W2787869143 cites W1853818383 @default.
• W2787869143 cites W1871999639 @default.
• W2787869143 cites W1954515006 @default.
• W2787869143 cites W1970499787 @default.
• W2787869143 cites W1977022270 @default.
• W2787869143 cites W1991656003 @default.
• W2787869143 cites W1994948218 @default.
• W2787869143 cites W2001532410 @default.
• W2787869143 cites W2008758052 @default.
• W2787869143 cites W2011000634 @default.
• W2787869143 cites W2011442758 @default.
• W2787869143 cites W2021616061 @default.
• W2787869143 cites W2033554291 @default.
• W2787869143 cites W2054367725 @default.
• W2787869143 cites W2058056848 @default.
• W2787869143 cites W2061680337 @default.
• W2787869143 cites W2079725471 @default.
• W2787869143 cites W2080103464 @default.
• W2787869143 cites W2086653737 @default.
• W2787869143 cites W2087882982 @default.
• W2787869143 cites W2096913799 @default.
• W2787869143 cites W2099000973 @default.
• W2787869143 cites W2099535971 @default.
• W2787869143 cites W2100315122 @default.
• W2787869143 cites W2104524178 @default.
• W2787869143 cites W2108666051 @default.
• W2787869143 cites W2110137106 @default.
• W2787869143 cites W2111012335 @default.
• W2787869143 cites W2112976515 @default.
• W2787869143 cites W2113040992 @default.
• W2787869143 cites W2114792070 @default.
• W2787869143 cites W2117576401 @default.
• W2787869143 cites W2128601571 @default.
• W2787869143 cites W2129529651 @default.
• W2787869143 cites W2132266605 @default.
• W2787869143 cites W2134253427 @default.
• W2787869143 cites W2135195813 @default.
• W2787869143 cites W2137167442 @default.
• W2787869143 cites W2143924924 @default.
• W2787869143 cites W2145327797 @default.
• W2787869143 cites W2147058464 @default.
• W2787869143 cites W2148606834 @default.
• W2787869143 cites W2149994587 @default.
• W2787869143 cites W2151382914 @default.
• W2787869143 cites W2151709086 @default.
• W2787869143 cites W2153966196 @default.
• W2787869143 cites W2159077599 @default.
• W2787869143 cites W2161387798 @default.
• W2787869143 cites W2161697947 @default.
• W2787869143 cites W2166969772 @default.
• W2787869143 cites W2169983032 @default.
• W2787869143 cites W2170147411 @default.
• W2787869143 cites W2170988125 @default.
• W2787869143 cites W2188964775 @default.
• W2787869143 cites W2194014097 @default.
• W2787869143 cites W2195518879 @default.
• W2787869143 cites W2221191201 @default.
• W2787869143 cites W2306410696 @default.
• W2787869143 cites W2322570510 @default.
• W2787869143 cites W2325363292 @default.
• W2787869143 cites W2404782822 @default.
• W2787869143 cites W2415959007 @default.
• W2787869143 cites W2466624553 @default.
• W2787869143 cites W2578010562 @default.
• W2787869143 cites W2604879851 @default.
• W2787869143 cites W2623464423 @default.
• W2787869143 cites W2731309476 @default.
• W2787869143 cites W2746178553 @default.
• W2787869143 cites W3143304884 @default.
• W2787869143 cites W4248056424 @default.
• W2787869143 doi "https://doi.org/10.1093/jnci/djx265" @default.
• W2787869143 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29361001" @default.
• W2787869143 hasPublicationYear "2018" @default.
• W2787869143 type Work @default.
• W2787869143 sameAs 2787869143 @default.

• next